CL-108 – is a novel bi-layered tablet containing 12.5mg of immediate release promethazine with a modified release of 7.5 mg of hydrocodone and 325mg of acetaminophen.  CL-108 is indicated for patients who suffer from moderate to severe acute pain while preventing Opioid Induced Nausea & Vomiting (OINV).   CL-108 is expected to treat any patient converted to the new combination from another pain regimen.